Unnamed: 0,title,date,stock,sentiment
680979.0,"Credit Suisse Maintains Neutral on Ironwood Pharmaceuticals, Lowers Price Target to $11",2020-06-01 08:54:00-04:00,IRWD,positive
680980.0,70 Biggest Movers From Yesterday,2020-05-28 06:09:00-04:00,IRWD,neutral
680981.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-27 12:19:00-04:00,IRWD,neutral
680982.0,"Ironwood And AbbVie Report Phase II Trial Of MD-7246 Did Not Achieve Statistically Significant Improvements In Abdominal Pain Relative To Placebo, Companies Plan To Discontinue Development",2020-05-27 08:14:00-04:00,IRWD,negative
680983.0,Ironwood Pharmaceuticals Option Alert: Nov 20 $15 Calls Sweep (21) near the Ask: 300 @ $1.101 vs 0 OI; Ref=$11.43,2020-05-18 10:02:00-04:00,IRWD,positive
680984.0,"HC Wainwright & Co. Reiterates Neutral on Ironwood Pharmaceuticals, Lowers Price Target to $11",2020-05-11 07:42:00-04:00,IRWD,negative
680985.0,"Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Lowers Price Target to $11",2020-05-07 08:40:00-04:00,IRWD,negative
680986.0,"Ironwood Pharmaceuticals Q1 EPS $0.040 Misses $0.050 Estimate, Sales $79.943M Beat $78.660M Estimate",2020-05-06 16:29:00-04:00,IRWD,negative
680987.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,IRWD,positive
680988.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,IRWD,neutral
680989.0,"Wells Fargo Maintains Overweight on Ironwood Pharmaceuticals, Lowers Price Target to $15",2020-04-30 11:36:00-04:00,IRWD,negative
680990.0,"Ironwood, Allergan Receive Notices Of Allowance For Patent Applications Covering 72 mcg Dose Of LINZESS",2020-04-28 16:07:00-04:00,IRWD,neutral
680991.0,"Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Lowers Price Target to $12",2020-04-15 10:15:00-04:00,IRWD,negative
680992.0,Ironwood Pharmaceuticals shares are trading lower after the company issued FY20 sales guidance below analyst estimates.,2020-02-14 14:29:00-05:00,IRWD,neutral
680993.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,IRWD,negative
680994.0,Ironwood Pharmaceuticals Sees FY20 Sales $360M-$380M Vs. $391.25M Est.,2020-02-13 07:25:00-05:00,IRWD,neutral
680995.0,"Ironwood Pharmaceuticals Q4 EPS $0.3 Beats $0.24 Estimate, Sales $126.301M Beat $111.85M Estimate",2020-02-13 07:24:00-05:00,IRWD,neutral
680996.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,IRWD,neutral
680997.0,"Ironwood And Allergan Announce Settlement With Teva Resolving LINZESS Patent Litigation; Settlement Does Not Grant License To Teva With Regard To 72 mcg Generic Version Of LINZESS, Grants Teva License To Market 145 mcg And 290 mcg Generics Starting 2029",2020-01-22 09:27:00-05:00,IRWD,positive
680998.0,Ironwood Pharmaceuticals shares are trading higher after the company and Allergan announced they have reached an agreement with Sandoz resolving patent litigation brought in response to Sandoz's ANDA seeking approval to market generic versions of LINZESS.,2020-01-06 15:54:00-05:00,IRWD,positive
680999.0,Ironwood Pharma and Allergan Resolve Patent Litigation in Response to Sandoz's New Drug Application,2020-01-06 08:06:00-05:00,IRWD,positive
681000.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,IRWD,neutral
681001.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,IRWD,negative
681002.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,IRWD,neutral
681003.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,IRWD,neutral
681004.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-19 10:29:00-05:00,IRWD,neutral
681005.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,IRWD,negative
681006.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-18 10:43:00-05:00,IRWD,neutral
681007.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,IRWD,positive
681008.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,IRWD,positive
681009.0,"Ironwood Pharmaceuticals Shares Up 2.78% For The Session; NOTE: Co. Previously Entered Gastrointestinal Disease Education And Promotional Agreement With Alnylam Pharmaceuticals For Givlaari, Which Today Received FDA Approval",2019-11-20 14:24:00-05:00,IRWD,positive
681010.0,Ironwood Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-10-31 12:40:00-04:00,IRWD,positive
681011.0,"Ironwood Pharmaceuticals Earlier Reported Q3 Adj. EPS $0.4 Beats $0.1 Estimate, Sales $131.167M Beat $96.38M Estimate",2019-10-31 09:08:00-04:00,IRWD,neutral
681012.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,IRWD,positive
681013.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,IRWD,neutral
681014.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,IRWD,neutral
681015.0,"Ironwood Pharmaceuticals, AstraZeneca Amend LINZESS Collaboration in China",2019-09-18 04:18:00-04:00,IRWD,neutral
681016.0,Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day,2019-09-04 16:42:00-04:00,IRWD,neutral
681017.0,"The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission",2019-08-16 07:33:00-04:00,IRWD,negative
681018.0,Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter US GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP),2019-08-13 07:31:00-04:00,IRWD,positive
681019.0,"Ironwood Pharmaceuticals Beginning On January 1, 2020, Co. Will No Longer Be Responsible For Supply Of Linaclotide API To Astellas",2019-08-01 17:14:00-04:00,IRWD,neutral
681020.0,Ironwood Pharmaceuticals' shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-07-31 11:22:00-04:00,IRWD,positive
681021.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,IRWD,positive
681022.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,IRWD,neutral
681023.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,IRWD,negative
681024.0,Credit Suisse Assumes Ironwood Pharmaceuticals at Neutral,2019-07-10 09:24:00-04:00,IRWD,positive
681025.0,Shares of multiple drugmakers and biotech companies are trading higher after AbbVie announced it will acquire Allergan.,2019-06-25 11:21:00-04:00,IRWD,positive
681026.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-06-19 12:23:00-04:00,IRWD,neutral
681027.0,"Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective",2019-06-19 10:22:00-04:00,IRWD,positive
681028.0,"The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut",2019-06-19 07:51:00-04:00,IRWD,positive
681029.0,"Ironwood, Allergan Report Topline Data From Phase IIIb Trial of LINZESSÂ® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation: Met All Primary, Secondary Endpoints",2019-06-18 16:10:00-04:00,IRWD,negative
681030.0,"Ironwood Pharma, Allergan Report Initiation Of Patient Dosing In Phase II Trial Of MD-7246 In Patients With Abdominal Pain Associated With IBS-D",2019-06-03 08:32:00-04:00,IRWD,negative
681031.0,60 Biggest Movers From Friday,2019-05-20 05:06:00-04:00,IRWD,neutral
681032.0,44 Stocks Moving In Friday's Mid-Day Session,2019-05-17 12:26:00-04:00,IRWD,neutral
681033.0,Ironwood Pharmaceuticals shares are trading higher after Sarissa Capital raised its stake in the company from 7.54 million shares to 9.49 million shares.,2019-05-17 10:23:00-04:00,IRWD,positive
681034.0,"Ironwood Pharma 13D Filing From Sarissa Capital Shows Raised Stake From ~7.54M Shares To ~9.49M Shares, Or 6.1% Stake",2019-05-16 16:59:00-04:00,IRWD,positive
681035.0,78 Biggest Movers From Yesterday,2019-05-03 05:08:00-04:00,IRWD,neutral
681036.0,54 Stocks Moving In Thursday's Mid-Day Session,2019-05-02 12:09:00-04:00,IRWD,neutral
681037.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,IRWD,positive
681038.0,Ironwood Pharmaceuticals ; Sees FY2019 Sales $370M-null390M vs $377.33M Est,2019-05-02 08:07:00-04:00,IRWD,neutral
681039.0,"Ironwood Pharmaceuticals Q1 EPS $(0.26) Misses $(0.18) Estimate, Sales $68.73M Miss $80.85M Estimate",2019-05-02 08:06:00-04:00,IRWD,negative
681040.0,Ironwood Pharmaceuticals shares are trading lower after the company said it expects 2019 sales to be below the analyst consensus estimate.,2019-04-02 09:42:00-04:00,IRWD,neutral
681041.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,IRWD,neutral
681042.0,Irownwood Pharma Sees FY19 Sales $370M-$390M vs $387.1M Estimate,2019-04-01 16:03:00-04:00,IRWD,neutral
681043.0,Ironwood Pharma Reports Completed Separation Of Cyclerion Therapeutics,2019-04-01 16:02:00-04:00,IRWD,neutral
681044.0,"UPDATE: Morgan Stanley Upgrades Ironwood Pharmaceuticals As Firm Expects 'Linzess growth to stabilize in 2019, with prescription MiraLAX and potential additional label claims being the driver'",2019-03-27 09:31:00-04:00,IRWD,positive
681045.0,"Benzinga's Top Upgrades, Downgrades For March 27, 2019",2019-03-27 09:17:00-04:00,IRWD,positive
681046.0,"Morgan Stanley Upgrades Ironwood Pharmaceuticals to Equal-Weight, Raises Price Target to $14",2019-03-27 06:37:00-04:00,IRWD,neutral
681047.0,Ironwood Pharma Reports Cyclerion Therapeutics Entered Deal For Private Placement OF Up To $175M,2019-02-26 09:12:00-05:00,IRWD,neutral
681048.0,"Benzinga's Top Upgrades, Downgrades For February 25, 2019",2019-02-25 09:14:00-05:00,IRWD,positive
681049.0,"H.C. Wainwright Upgrades Ironwood Pharmaceuticals to Neutral, Raises Price Target to $14",2019-02-25 07:28:00-05:00,IRWD,neutral
681050.0,58 Biggest Movers From Yesterday,2019-02-14 05:35:00-05:00,IRWD,neutral
681051.0,42 Stocks Moving In Wednesday's Mid-Day Session,2019-02-13 12:25:00-05:00,IRWD,neutral
681052.0,"Ironwood Pharmaceuticals shares are trading higher after the company reported Q4 EPS of $(0.10), beating the $(0.15) estimate and sales of $130.69 million, beating the $98.47 million estimate.",2019-02-13 10:29:00-05:00,IRWD,negative
681053.0,"The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering",2019-02-13 07:49:00-05:00,IRWD,negative
681054.0,"Ironwood Pharmaceuticals Q4 EPS $(0.10) Beats $(0.15) Estimate, Sales $130.69M Beat $98.47M Estimate",2019-02-13 07:16:00-05:00,IRWD,neutral
681055.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,IRWD,neutral
681056.0,10 Biggest Price Target Changes For Thursday,2019-01-24 09:51:00-05:00,IRWD,neutral
681057.0,"Benzinga's Top Upgrades, Downgrades For January 24, 2019",2019-01-24 09:02:00-05:00,IRWD,positive
681058.0,Ironwood Pharma Announces Julie McHugh to Serve as Chair of the Board,2019-01-24 08:04:00-05:00,IRWD,neutral
681059.0,"The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial",2019-01-24 07:45:00-05:00,IRWD,negative
681060.0,"JP Morgan Upgrades Ironwood Pharmaceuticals to Neutral, Raises Price Target to $13",2019-01-24 06:22:00-05:00,IRWD,positive
681061.0,Irownwood Pharma Reports Initiation Of Phase 1 Trial Of IW-6463,2019-01-23 16:01:00-05:00,IRWD,neutral
681062.0,Ironwood Pharmaceuticals Receives Approval Of LINZESS In China For Treatment Of Adults With IBS-C,2019-01-15 08:03:00-05:00,IRWD,positive
681063.0,Ironwood Pharmaceuticals Appoints Mark Mallon CEO,2019-01-04 12:07:00-05:00,IRWD,neutral
681064.0,Ironwood Pharmaceuticals Picks AztraZeneca Executive To Be Next CEO,2019-01-04 11:15:00-05:00,IRWD,neutral
681065.0,"The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen",2019-01-03 07:36:00-05:00,IRWD,negative
681066.0,Ironwood And Allergan Announce Settlement With Mylan Resolving LINZESS Patent Litigation; Additional Details Not Disclosed,2019-01-02 16:03:00-05:00,IRWD,positive
681067.0,When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?,2018-12-21 13:38:00-05:00,IRWD,negative
681068.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,IRWD,negative
681069.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,IRWD,positive
681070.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,IRWD,positive
681071.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,IRWD,negative
681072.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,IRWD,negative
681073.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,IRWD,negative
681074.0,"Benzinga's Top Upgrades, Downgrades For November 7, 2018",2018-11-07 09:14:00-05:00,IRWD,positive
681075.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,IRWD,negative
681076.0,JP Morgan Downgrades Ironwood Pharmaceuticals to Underweight,2018-11-07 06:27:00-05:00,IRWD,positive
681077.0,Credit Suisse Downgrades Ironwood Pharmaceuticals to Neutral,2018-11-07 06:26:00-05:00,IRWD,positive
681078.0,"Ironwood Pharmaceuticals Q3 Adj. EPS $(0.38) Misses $(0.17) Estimate, Sales $65.686M Miss $93.63M Estimate",2018-11-06 08:42:00-05:00,IRWD,negative
681079.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,IRWD,positive
681080.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,IRWD,neutral
681081.0,64 Biggest Movers From Yesterday,2018-10-31 05:00:00-04:00,IRWD,neutral
681082.0,55 Stocks Moving In Tuesday's Mid-Day Session,2018-10-30 13:32:00-04:00,IRWD,neutral
681083.0,Ironwood Pharma Reports FDA Fast Track Designation For Praliciguat For Treatment Of Heart Failure with Preserved Ejection Fraction,2018-09-13 08:00:00-04:00,IRWD,negative
681084.0,Ironwood Pharmaceuticals shares down 7.5% after the company missed Q2 earnings estimates.,2018-08-06 15:32:00-04:00,IRWD,neutral
681085.0,Earlier Ironwood Pharma Announced Termination of Its Licensing Agreement With AstraZeneca for U.S. Lesinurad Franchise,2018-08-06 08:55:00-04:00,IRWD,positive
681086.0,"Ironwood Pharmaceuticals Q2 Adj. EPS $(0.28) Misses $(0.21) Estimate, Sales $81.106M Miss $82.6M Estimate",2018-08-06 08:03:00-04:00,IRWD,negative
681087.0,"Ironwood Pharmaceuticals Q2 GAAP EPS $(0.32) Misses $(0.21) Estimate, Sales $81.106M Miss $82.6M Estimate",2018-08-06 08:01:00-04:00,IRWD,negative
681088.0,"Benzinga's Top Upgrades, Downgrades For July 23, 2018",2018-07-23 09:18:00-04:00,IRWD,positive
681089.0,"H.C. Wainwright Initiates Coverage On Ironwood Pharmaceuticals with Sell Rating, Announces $12.50 Price Target",2018-07-23 07:05:00-04:00,IRWD,neutral
681090.0,Delivering Alpha 2018: Everything You Need To Know,2018-07-19 08:48:00-04:00,IRWD,neutral
681091.0,"From Delivering Alpha Conference: Alex Denner Of Sarissa Capital Says Likes Ironwood Pharma, Medicines Co.",2018-07-18 15:11:00-04:00,IRWD,positive
681092.0,"Benzinga's Top Upgrades, Downgrades For July 18, 2018",2018-07-18 09:19:00-04:00,IRWD,positive
681093.0,Cowen & Co. Downgrades Ironwood Pharmaceuticals to Market Perform,2018-07-18 07:47:00-04:00,IRWD,neutral
681094.0,Ironwood Pharmaceuticals Starts Phase IIIb Study of Linaclotide,2018-07-16 08:01:00-04:00,IRWD,neutral
681095.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,IRWD,neutral
681096.0,Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at #ADA2018,2018-06-23 19:16:00-04:00,IRWD,positive
681097.0,Ironwood Pharma Initiates Pivotal Phase III Program for IW-3718,2018-06-21 16:07:00-04:00,IRWD,neutral
681098.0,Ironwood Pharmaceuticals To Highlight Clinical And Preclinical Data For Praliciguat At American Diabetes Association's 78th Scientific Sessions,2018-06-20 08:05:00-04:00,IRWD,positive
681099.0,"Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs",2018-06-08 09:20:00-04:00,IRWD,positive
681100.0,Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation For Olinciguat For Treatment Of Sickle Cell Disease,2018-06-07 16:07:00-04:00,IRWD,neutral
681101.0,Hearing Ironwood's olinciguat Granted FDA Orphan Drug Designation,2018-06-06 13:14:00-04:00,IRWD,positive
681102.0,Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals,2018-06-06 04:42:00-04:00,IRWD,positive
681103.0,Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements In Heartburn And Regurgitation Symptoms In Patients With Persistent GERD At Digestive Disease Week 2018,2018-06-05 16:06:00-04:00,IRWD,positive
681104.0,"Ironwood Pharma Shareholder Sarissa Capital Issues Statement On Co., Says Plan To Separate Co.'s R&D Programs From Commercial Unit Is 'Good First Step Toward Creating Shareholder Value...'",2018-05-31 07:09:00-04:00,IRWD,positive
681105.0,"Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees, Urges Shareholders to Vote ""FOR"" the Ironwood Director Nominees on the WHITE Proxy Card",2018-05-14 07:32:00-04:00,IRWD,neutral
681106.0,"Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate",2018-05-09 10:13:00-04:00,IRWD,negative
681107.0,"Benzinga's Top Upgrades, Downgrades For May 9, 2018",2018-05-09 09:13:00-04:00,IRWD,positive
681108.0,"Ironwood Pharmaceuticals Board Urges Shareholders to Vote ""FOR"" all Three of Ironwood's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY",2018-05-09 08:32:00-04:00,IRWD,neutral
681109.0,Morgan Stanley Downgrades Ironwood Pharmaceuticals to Underweight,2018-05-09 07:17:00-04:00,IRWD,neutral
681110.0,Ironwood and Allergan Announce Settlement With Aurobindo Pharma Over LINZESS Patent Litigation,2018-05-03 17:08:00-04:00,IRWD,negative
681111.0,"Benzinga's Top Upgrades, Downgrades For May 2, 2018",2018-05-02 09:15:00-04:00,IRWD,positive
681112.0,UPDATE: Ironwood Urges Holders To Vote On WHITE Proxy Card For All Co. Director Nominees,2018-05-02 08:18:00-04:00,IRWD,neutral
681113.0,"Ironwood Files Proxy Materials, Sends Letter To Holders",2018-05-02 08:18:00-04:00,IRWD,neutral
681114.0,Mizuho Upgrades Ironwood Pharmaceuticals to Buy,2018-05-02 08:10:00-04:00,IRWD,neutral
681115.0,Ironwood Pharma Shares Down ~9% Following Earlier Resumption,2018-05-01 08:56:00-04:00,IRWD,positive
681116.0,Ironwood Sees Incurring Charges Related To Separation Deal; Will Offer Update On Impact Of Transaction Charges On FY18 During Q2 Investor Update,2018-05-01 08:16:00-04:00,IRWD,negative
681117.0,UPDATE: Ironwood Pharma Says Separation Of Units Expected To Result In 2 Independent Publicly Traded Cos.,2018-05-01 08:15:00-04:00,IRWD,neutral
681118.0,"Ironwood Reports Intent To Separate Soluble Guanylate Cyclase Business From Commercial, Gastrointestinal Business",2018-05-01 08:14:00-04:00,IRWD,neutral
681119.0,Ironwood Pharma Shares To Resume Trade At 8:30 a.m. EDT,2018-05-01 08:08:00-04:00,IRWD,positive
681120.0,Ironwood Pharma Says Will Initiate Phase III Program For IW-3718 During Q3'18,2018-05-01 07:56:00-04:00,IRWD,neutral
681121.0,"Ironwood Pharma Q1 Adj. EPS $(0.27) Misses $(0.23) Est., Sales $69.155M Misses $78.9M Est.",2018-05-01 07:56:00-04:00,IRWD,negative
681122.0,Ironwood Pharma Shares Halted News Pending,2018-05-01 07:50:00-04:00,IRWD,positive
681123.0,Ironwood Pharma Shares Up 13.9%; Earlier Co Announced Receipt Of Notice From Sarissa Capital Mgmt That It Intends To Nominate Its CIO To The Co.'s Board,2018-04-09 13:50:00-04:00,IRWD,positive
681124.0,Ironwood Pharmaceuticals Reports Q4 Sales $94.2M vs $88M Est.,2018-02-15 08:12:00-05:00,IRWD,neutral
681125.0,Ironwood Sees Sales From Linaclotide API Sales To Astellas Pharma $20M+,2018-01-08 11:14:00-05:00,IRWD,neutral
681126.0,Ironwood Pharma 8-K Shows Expectation For US Sales Of LINZESS ~$700M In FY17,2018-01-08 11:13:00-05:00,IRWD,neutral
681127.0,BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A,2018-01-05 17:31:00-05:00,IRWD,positive
681128.0,Bank of America Downgrades Ironwood Pharmaceuticals From Buy to Underperform,2018-01-05 08:34:00-05:00,IRWD,neutral
681129.0,Ironwood Pharma Reports Initiation Of Phase II Trial Of sGC Stimulator IW-1701 In Patients With Sickle Cell Disease,2017-12-21 08:04:00-05:00,IRWD,neutral
681130.0,"The Market In 5 Minutes: Apple And China, Trump And Jerusalem, And Bitcoin",2017-12-06 08:57:00-05:00,IRWD,neutral
681131.0,Mizuho Downgrades Ironwood Pharmaceuticals to Neutral,2017-12-06 06:48:00-05:00,IRWD,neutral
681132.0,"Ironwood Pharma Shares Tick To Session Lows, Down 2.4%, As Hearing Morgan Stanley Issued Cautious Comments On Co./Stock",2017-12-04 10:22:00-05:00,IRWD,neutral
681133.0,UPDATE: Ironwood Pharma Says 'Data support advancement of IW-1973 for evaluation as a potential treatment for patients with diabetic nephropathy and for patients with heart failure with preserved ejection fraction',2017-12-04 08:27:00-05:00,IRWD,negative
681134.0,"Ironwood Pharma Reports Top-Line Phase IIa Data From IW-1973: 'Addition of IW-1973 to ongoing medical regimens used to treat diabetic patients with hypertension showed reductions in blood pressure, fasting plasma glucose, cholesterol and triglycerides...'",2017-12-04 08:27:00-05:00,IRWD,positive
681135.0,Ironwood Pharma Names William Huyett COO; Gina Consylman Promoted To CFO Role,2017-11-28 08:00:00-05:00,IRWD,positive
681136.0,Could The Street Be Underappreciating The Ironwood Pharma Pipeline?,2017-11-27 13:31:00-05:00,IRWD,neutral
681137.0,"Credit Suisse Initiates Coverage On Ironwood Pharmaceuticals with Outperform Rating, Announces $19.00 Price Target",2017-11-27 08:34:00-05:00,IRWD,positive
681138.0,Seeing Notable Block Trade In Ironwood Pharmaceuticals Of 2.3M Shares At $15.50/Share,2017-11-20 14:40:00-05:00,IRWD,negative
681139.0,"Credit Suisse Healthcare ConferencE Concludes Today, Presenters Include: Community Health Systems, Innoviva, Ironwood Pharmaceuticals, Ignyta, Alnylam, and HCA Healthcare",2017-11-08 09:27:00-05:00,IRWD,positive
681140.0,Ironwood Pharma S-3 Shows Registration For Mixed Securities Shelf Offering,2017-11-02 17:46:00-04:00,IRWD,positive
681141.0,"Ironwood Pharma Q3 Adj. EPS $(0.18) vs $(0.24) Est., Sales $86.8M vs $73.6M Est.",2017-11-02 08:05:00-04:00,IRWD,neutral
681142.0,Seeing Notable Block Trade In Ironwood Pharmaceuticals Of 1.8M Shares At $15.25/Share,2017-10-17 13:19:00-04:00,IRWD,negative
681143.0,"Morgan Stanley Healthcare Conference Concludes Today, Presenters Include Ironwood Pharmaceuticals, Sage Therapeutics, Pfizer, TherapeuticsMD, Alnylam, bluebird bio, and Cigna",2017-09-13 09:24:00-04:00,IRWD,neutral
681144.0,"Wells Fargo Healthcare Conference Concludes Today, Presenters Include: Foundation Medicine, Tenet Healthcare, bluebird bio, Envision Healthcare, Ironwood Pharmaceuticals, Quorum Health, and Concert Pharmaceuticals",2017-09-07 08:58:00-04:00,IRWD,positive
681145.0,Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout,2017-08-21 08:05:00-04:00,IRWD,positive
681146.0,Watch These 7 Huge Put Purchases In Friday Trade,2017-08-04 04:11:00-04:00,IRWD,positive
681147.0,"Ironwood Reports Q2 Adj. EPS $(0.28) vs $(0.22) Est., Sales $65.1M vs $70.82M Est.",2017-08-03 16:27:00-04:00,IRWD,neutral
681148.0,Benzinga's Option Alert Recap From August 3,2017-08-03 16:09:00-04:00,IRWD,positive
681149.0,Ironwood Pharm Option Alert: Sep 15 $15 Puts at the Bid: 1000 @ $0.6 vs 0 OI; Ref=$16.635,2017-08-03 11:10:00-04:00,IRWD,positive
681150.0,"Ironwood's Pipeline Needs Work, Analyst Downgrades",2017-07-21 10:47:00-04:00,IRWD,neutral
681151.0,JP Morgan Downgrades Ironwood Pharmaceuticals to Neutral,2017-07-21 07:18:00-04:00,IRWD,positive
681152.0,"UPDATE: Ironwood Says 'IW-3718 1500 mg also showed reductions in regurgitation frequency,' Will Advanced Into Phase III",2017-07-20 08:12:00-04:00,IRWD,positive
681153.0,UPDATE: Ironwood Says 'Greater than 50% of patients treated with IW-3718 1500 mg achieved a clinically meaningful reduction in heartburn severity',2017-07-20 08:12:00-04:00,IRWD,positive
681154.0,Ironwood Pharma Reports Top-Line Results From IW-3718 Phase IIb Trial In Uncontrolled Gastroesophageal Reflux Disease: Showed 'significant reduction in heartburn severity in patients with uncontrolled GERD',2017-07-20 08:11:00-04:00,IRWD,negative
681155.0,"Goldman Sachs Global Healthcare Conference Concludes Today, Presenters Include: Gilead, Tesaro, Ironwood Pharmaceuticals and Alkermes",2017-06-15 08:52:00-04:00,IRWD,neutral
681156.0,"Jefferies Health Care Conference Continues Today, Presenters Include: Ligand, Immunogen, TherapeuticsMD, Synergy Pharma, Ironwood, Acadia, Community Health Systems, & Celldex",2017-06-08 08:37:00-04:00,IRWD,positive
681157.0,"Bank Of America Health Care Conference Continues Today; Presenters Include Celgene, Ionis, Neurocrine Biosciences, Cigna, GW Pharma, Allergan, Ironwood Pharma, Tenet Healthcare, Civitas Solutions, & Amgen",2017-05-17 09:03:00-04:00,IRWD,positive
681158.0,"Ironwood Pharmaceuticals  Says LINZESS U.S. Net Sales Grew To $148M In Q1 2017, Remains On Track To Exceed $1B In U.S. Annual Sales By 2020",2017-05-08 08:05:00-04:00,IRWD,neutral
681159.0,Wells Fargo Initiates Coverage On Ironwood Pharmaceuticals with Outperform Rating,2017-05-03 08:02:00-04:00,IRWD,positive
681160.0,"Barclays Global Healthcare Conference Concludes Today; Presenters Include DexCom, NantKwest, Juno, Humana, And Ironwood Pharma",2017-03-16 08:36:00-04:00,IRWD,neutral
681161.0,Ironwood Pharmaceuticals Holding R&D Day Today,2017-03-09 08:21:00-05:00,IRWD,neutral
681162.0,"Ironwood Pharmaceuticals Reports Q4 Adj. EPS $(0.12) vs $(0.24) Est., Sales $87.459M vs $77.34M Est.",2017-02-21 16:24:00-05:00,IRWD,neutral
681163.0,"Astellas, Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan",2017-01-29 19:03:00-05:00,IRWD,positive
681164.0,Allergan and Ironwood Pharmaceuticals Reports U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS,2017-01-26 07:05:00-05:00,IRWD,positive
681165.0,Ironwood Pharmaceuticals Sees Continued Strong LINZESS Growth and Margin Expansion in 2017 at #JPM17,2017-01-08 21:29:00-05:00,IRWD,positive
681166.0,Ironwood Announces New Drug Application for DUZALLO Has Been Accepted For FDA Review,2017-01-04 08:04:00-05:00,IRWD,positive
681167.0,Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 in IBS-C,2016-12-22 07:02:00-05:00,IRWD,positive
681168.0,Ironwood Pharma Gets Japanese Approval of LINZESS for IBS-C,2016-12-19 06:05:00-05:00,IRWD,positive
681169.0,"UPDATE: Ironwood Reports Analysis Found that Patients Treated with Lesinurad Plus Allopurinol in CLEAR 1 and CLEAR 2 trials who Continued Treatment in the CLEAR Extension Study, Maintained Target sUA Levels over Full Two Years",2016-11-13 08:18:00-05:00,IRWD,positive
681170.0,Ironwood Highlights ZURAMPIC Phase III Extension Study Data at American College of Rheumatology 2016 Annual Meeting,2016-11-13 08:09:00-05:00,IRWD,neutral
681171.0,"Ironwood Pharma Reports Q3 Adj. EPS $(0.18) vs $(0.24) Est.; Reduces Expectation to Use Less Than $50M in Cash for Operations During '16, Down from Forecast of Less Than $70M Previously",2016-11-03 08:14:00-04:00,IRWD,neutral
681172.0,Ironwood Pharma Reports US Availability of ZURAMPIC 200 mg Tablets for Patients with Uncontrolled Gout,2016-10-03 07:34:00-04:00,IRWD,negative
681173.0,20 Stocks Which Rallied Three Days On Increasing Volume,2016-09-23 09:19:00-04:00,IRWD,neutral
681174.0,BTIG Raises Ironwood Pharmaceuticals Price Target Ahead Of New Drug Launch,2016-09-22 11:31:00-04:00,IRWD,neutral
681175.0,10 Stocks With Three-Day Increasing Volume,2016-09-22 08:53:00-04:00,IRWD,neutral
681176.0,Ironwood Pharmaceuticals Reports Q2 EPS $(0.16) vs. Est. $(0.15),2016-08-04 17:45:00-04:00,IRWD,neutral
681177.0,"Ironwood Pharma, Allergan Report sNDA for 72 mcg Linaclotide in Chronic Idiopathic Constipation Accepted for FDA Review",2016-06-09 08:02:00-04:00,IRWD,positive
681178.0,Ironwood Pharmaceuticals Closes Transaction with AstraZeneca for US Rights to Lesinurad,2016-06-03 04:18:00-04:00,IRWD,neutral
681179.0,"IronWood Q1 EPS ($0.08) vs ($0.14) est, Revenue $66.0M vs $53.6M est",2016-05-09 17:18:00-04:00,IRWD,neutral
681180.0,Andrew Acker Speculating IRWD Could Be Bought By AGN,2016-05-04 10:02:00-04:00,IRWD,neutral
681181.0,Option Alert: SWEEP (BUY) - IRWD June $22.5 Put - 522 @ 11.462 in 76 orders. 522 traded. OI: 0,2016-04-28 12:12:00-04:00,IRWD,positive
681182.0,Adam Feuerstein Retweets Jacob Plieth: I've had it confirmed that $IRWD report was removed from @PhaseVResearch site & Seekingalpha in response to complaint from FAERS data source,2016-04-28 12:06:00-04:00,IRWD,negative
681183.0,UPDATE: Appears Entire Phase Five Website is Down,2016-04-28 11:09:00-04:00,IRWD,neutral
681184.0,Hearing Phase Five Research Removed Short Report on Ironwood from Website,2016-04-28 11:06:00-04:00,IRWD,neutral
681185.0,Iroonwood Shares Spiking To $10.71/Share,2016-04-28 11:05:00-04:00,IRWD,positive
681186.0,Merrill Lynch Says Link Unlikely Between The 7 Reported AERS Deaths And Linzess,2016-04-26 14:25:00-04:00,IRWD,neutral
681187.0,Mid-Afternoon Market Update: Crude Oil Up 3%; Amira Nature Foods Shares Tumble,2016-04-26 14:20:00-04:00,IRWD,negative
681188.0,Ironwood Pharma Sells Off to Low of $9.69; May be Attributed to Short Piece from Phase Five Research,2016-04-26 10:55:00-04:00,IRWD,negative
681189.0,Option Alert: IRWD May16 5.0 Puts Sweep: 830 @  ASK  $0.10: 830 traded vs 1899 OI:  Earnings 5/3  $9.76 Ref,2016-04-26 10:54:00-04:00,IRWD,positive
681190.0,Traders Attributing Weakness in Ironwood to Negative Report from Phase Five Research,2016-04-26 10:53:00-04:00,IRWD,negative
681191.0,Astrazeneca Announces US Licensing Agreement With Ironwood; Includes US Rights to Zurampic; Lesinurad/Allopurinol Fixed-Dose Combination in Gout,2016-04-26 04:34:00-04:00,IRWD,positive
681192.0,Benzinga's Top Upgrades,2016-04-06 09:12:00-04:00,IRWD,positive
681193.0,Cowen & Company Upgrades Ironwood Pharmaceuticals to Outperform,2016-04-06 07:03:00-04:00,IRWD,neutral
681194.0,Ironwood Pharmaceuticals Falls 6% Following Disappointing Phase 2a Study,2016-04-05 09:34:00-04:00,IRWD,negative
681195.0,Ironwood Pharmaceutical Shares Down $0.70 At $10.50 After IW-9179 Reports They Will Discontinue Development On Poor Top-Line Data,2016-04-05 08:55:00-04:00,IRWD,negative
681196.0,Ironwood Pharma Reports Top-Line Data from Exploratory Phase IIa Study of IW-9179 in DG,2016-04-05 08:01:00-04:00,IRWD,neutral
681197.0,Ironwood Pharmaceuticals Starts Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease,2016-03-23 08:03:00-04:00,IRWD,neutral
681198.0,Benzinga's Top Initiations,2016-03-21 10:07:00-04:00,IRWD,positive
681199.0,"Goldman Sachs Initiates Coverage on Ironwood Pharmaceuticals at Neutral, Announces $14.00 PT, Likes LT Opportunity Coming From Pipeline Optionality",2016-03-21 07:53:00-04:00,IRWD,positive
681200.0,Ironwood Pharma Reports Filing by Astellas of NDA in Japan with Linaclotide for Treatment of Adults with IBS-C,2016-02-24 08:02:00-05:00,IRWD,neutral
681201.0,Shares Of Ironwood Spike Higher,2016-02-19 10:01:00-05:00,IRWD,positive
681202.0,Ironwood Pharma Spikes to High of $9.05 on Volume,2016-02-19 10:01:00-05:00,IRWD,neutral
681203.0,Ironwood Sees FY16 Opex $255M-$285M,2016-02-18 16:18:00-05:00,IRWD,neutral
681204.0,Ironwood Pharma Reports Prelim. Q4 Adj. EPS ~$(0.10) vs $(0.17) Est.,2016-02-18 16:17:00-05:00,IRWD,neutral
681205.0,UPDATE: Ironwood Says Expects to Initiate Multiple Phase II Studies in 2016,2016-02-18 08:04:00-05:00,IRWD,neutral
681206.0,Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701,2016-02-18 08:00:00-05:00,IRWD,positive
681207.0,"Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside",2016-01-12 10:45:00-05:00,IRWD,negative
681208.0,"Ironwood Pharmaceuticals Expects $1B In LINZESS Annual net Sales By 202, More Than $2B linaclotide US Peak Sale Potential",2016-01-11 09:05:00-05:00,IRWD,neutral
681209.0,Benzinga's Top Initiations,2016-01-08 09:37:00-05:00,IRWD,positive
681210.0,"Mizuho Securities Initiates Coverage on Ironwood Pharmaceuticals at Buy, Announces $15.00 PT",2016-01-08 08:13:00-05:00,IRWD,positive
681211.0,"Wedbush Offers Weekly Retail Sales Tracker for Recently-Launched Drugs: Ironwood's LINZESS Total Scrips Up 0.4% WoW, New Scrips Down 0.8% WoW, Repeat Scrips Up 1.4% WoW",2015-12-28 10:50:00-05:00,IRWD,positive
681212.0,"BTIG Earlier Initiated Ironwood Pharma with Buy Rating, $15 Target, Cited 'improving visibility with its GI-focused pipeline'",2015-12-11 13:55:00-05:00,IRWD,positive
681213.0,"BZ NOTE: While Astellas, Ironwood Top-Line Data Was Positive; Diarrhea Rates In Trial For Linaclotide Registered 9.6% vs. 0.4% For Placebo",2015-11-30 16:10:00-05:00,IRWD,positive
681214.0,"Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan, Has Met All Primary Endpoints In All 8 Phase III/IIIb Clinical Trials",2015-11-30 16:07:00-05:00,IRWD,positive
681215.0,"UPDATE: Ironwood, Allergan to Make Decision Related to Advancement of OIC Program Following Review of Results from Linaclotide Colonic Release Phase IIB Trial",2015-11-30 08:03:00-05:00,IRWD,neutral
681216.0,UPDATE: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation,2015-11-30 08:00:00-05:00,IRWD,positive
681217.0,Ironwood Offers Top-Line Data from Phase 3 Trial of Linaclotide: Says Met Primary Endpoint,2015-11-30 08:00:00-05:00,IRWD,neutral
681218.0,"Ironwood Reported Q3 GAAP Loss of $0.33/Share, Adj. Loss of $0.25/Share vs Loss of $0.20/Share Est.",2015-11-03 17:28:00-05:00,IRWD,negative
681219.0,"Ironwood, Allergan Announce Initiation of Phase IIb Trial of Linaclotide Colonic Release",2015-11-02 08:06:00-05:00,IRWD,neutral
681220.0,US Stock Futures Edge Lower Ahead Of Earnings,2015-10-27 06:37:00-04:00,IRWD,negative
681221.0,Allergan Acquires Rights to Ironwood's CONSTELLA from Almirall 40+ Countries,2015-10-27 04:15:00-04:00,IRWD,neutral
681222.0,Ironwood Reports Positive Top-Line Results from Phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation,2015-10-13 16:01:00-04:00,IRWD,positive
681223.0,"Ironwood Pharma Reports Q2 Loss of $0.34/Share vs Loss of $0.22/Share Est., Sales $27.7M vs $36.5M Est.",2015-08-05 16:35:00-04:00,IRWD,negative
681224.0,Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.,2015-08-05 09:25:00-04:00,IRWD,neutral
681225.0,Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973,2015-07-22 07:34:00-04:00,IRWD,positive
681226.0,New Studies And Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials,2015-07-09 08:30:00-04:00,IRWD,neutral
681227.0,Benzinga's Top #PreMarket Gainers,2015-07-08 08:12:00-04:00,IRWD,positive
681228.0,"AstraZeneca, Ironwood Announce Positive Top-Line Data from Phase III IBS-C Trial Designed to Support Linaclotide Approval in China",2015-07-08 08:00:00-04:00,IRWD,positive
681229.0,JP Morgan Defends Ironwood Pharma,2015-06-17 11:15:00-04:00,IRWD,positive
681230.0,"Wedbush Cuts Target on Ironwood Pharma from $13 to $11, Highlights Positive Ph3 for Potential Linzess Competitor Plecanatide",2015-06-17 11:11:00-04:00,IRWD,positive
681231.0,Ironwood Pharmaceuticals Prices $300M of Convertible Senior Notes,2015-06-10 08:01:00-04:00,IRWD,neutral
681232.0,Benzinga's Top Initiations,2015-04-27 09:17:00-04:00,IRWD,positive
681233.0,"Bank of America Initiates Coverage on Ironwood Pharmaceuticals at Buy, Announces $19.00 PT",2015-04-27 07:52:00-04:00,IRWD,neutral
681234.0,Ironwood Pharma Shares Move Higher After-Hours on Daily Mail Report it Could be Takeover Target,2015-03-19 18:31:00-04:00,IRWD,positive
681235.0,"Friday's After-Hours Movers: Akorn, Rosetta Resources And More",2015-03-13 17:42:00-04:00,IRWD,neutral
681236.0,Exact Sciences & Ironwood Enter Co-Promotion For Cologuard,2015-03-09 11:32:00-04:00,IRWD,neutral
681237.0,Ironwood Pharma Initiates Phase 1 Clincal Study of sGC Stimulator IW-1973,2015-03-05 08:28:00-05:00,IRWD,neutral
681238.0,Ironwood Pharmaceuticals Initiates Phase I Clinical Study of Sgc Stimulator IW-1973,2015-03-05 08:04:00-05:00,IRWD,neutral
681239.0,Barclays Expands Coverage To 7 New Biotech Stocks,2015-03-04 11:29:00-05:00,IRWD,positive
681240.0,"Barclays Initiates Coverage on Ironwood Pharmaceuticals at Equal-weight, Announces $18.00 PT",2015-03-04 06:38:00-05:00,IRWD,neutral
681241.0,"Ironwood Pharma Reports Q4 EPS Loss $0.27 Vs Est $0.21, Sales $38.1M",2015-02-12 16:06:00-05:00,IRWD,negative
681242.0,Cantor Fitzgerald Upgrades Ironwood Pharmaceuticals to Hold,2015-02-06 06:54:00-05:00,IRWD,neutral
681243.0,Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease,2015-02-04 08:05:00-05:00,IRWD,positive
681244.0,The World's Top 10 Financial Bloggers,2015-01-13 13:22:00-05:00,IRWD,positive
681245.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,IRWD,neutral
681246.0,Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179,2014-12-09 08:01:00-05:00,IRWD,neutral
681247.0,Ironwood Earns $15M Payment From Astellas,2014-11-20 09:02:00-05:00,IRWD,neutral
681248.0,Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide ,2014-11-04 16:07:00-05:00,IRWD,neutral
681249.0,"Ironwood Pharmaceuticals, Inc. Reports Q3 EPS of $(0.30) vs $(0.32) Est",2014-11-04 16:03:00-05:00,IRWD,neutral
681250.0,Ironwood Presents IW-9179 Phase IIa Data At American College Of Gastroenterology 2014 Annual Scientific Meeting,2014-10-20 08:09:00-04:00,IRWD,neutral
681251.0,Ironwood Pharmaceuticals Announces Initiation Of Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation,2014-10-16 08:01:00-04:00,IRWD,neutral
681252.0,Markets Open Higher; VeriFone Profit Tops Street View,2014-09-04 11:31:00-04:00,IRWD,positive
681253.0,Benzinga's Top Downgrades,2014-09-04 08:57:00-04:00,IRWD,positive
681254.0,Cowen & Company Downgrades Ironwood Pharmaceuticals To Market Perform,2014-09-04 08:32:00-04:00,IRWD,neutral
681255.0,"Cowen & Company Downgrades Ironwood Pharmaceuticals, Inc. to Market Perform, Lowers PT to $10.50",2014-09-04 06:28:00-04:00,IRWD,negative
681256.0,Ironwood Names Thomas Graney as CFO,2014-09-02 17:02:00-04:00,IRWD,neutral
681257.0,"Ironwood Pharmaceuticals, Inc. Reports Q2 EPS of $(0.44) vs $(0.36) Est; Revenue of $6.84M vs $15.57M Est",2014-08-04 16:02:00-04:00,IRWD,neutral
681258.0,"Furey Research Initiates Coverage on Ironwood Pharmaceuticals, Inc. at Buy, Announces $20.00 PT",2014-07-09 06:48:00-04:00,IRWD,neutral
681259.0,Wallachbeth Capital Initiated Coverage on Ironwood Pharma with a Hold Rating and $16 Price Target,2014-06-18 10:25:00-04:00,IRWD,neutral
681260.0,Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th,2014-06-10 11:04:00-04:00,IRWD,neutral
681261.0,"Ironwood Pharmaceuticals Chairman Roberts Sells 411,154 Shares @$14.52/Share -Form 4",2014-06-03 17:20:00-04:00,IRWD,positive
681262.0,"Option Alert: Ironwood Pharma Jun $12.5 Put; 1,600 Contracts Traded vs 1,059 OI; Currently $13.64",2014-05-16 09:40:00-04:00,IRWD,positive
681263.0,Ironwood Pharmaceuticals Prices 13.725M Share Offering at $12.75/Share,2014-02-12 05:43:00-05:00,IRWD,positive
681264.0,Ironwood Pharmaceuticals Announces $150M Proposed Public Offering of Common Stock,2014-02-10 16:12:00-05:00,IRWD,neutral
681265.0,Mid-Day Market Update: Dow Tumbles Over 100 Points; Signature Bank Shares Gain On Strong Earnings,2014-01-21 12:58:00-05:00,IRWD,positive
681266.0,Mid-Morning Market Update: Markets Mixed; Verizon Posts Q4 Profit,2014-01-21 10:56:00-05:00,IRWD,positive
681267.0,"Ironwood Pharmaceuticals, Inc. Reports Q4 EPS of $(0.43) vs $(0.50) Est; Revenue of $5.03M vs $7.13M Est",2014-01-21 07:13:00-05:00,IRWD,neutral
681268.0,"Ironwood Pharma Will Cut ~10% of Jobs, Sees $4-4.5M Charge",2014-01-08 09:15:00-05:00,IRWD,negative
681269.0,"Option Alert: Ironwood Pharmaceuticals May $20 Call; 2,669 Contract Trade at Ask @$0.30; Currently $10.50",2013-12-18 13:31:00-05:00,IRWD,positive
681270.0,Ironwood Pharma Says Exploring Ways to Strengthen Linzess Clinical Profile ,2013-12-12 08:00:00-05:00,IRWD,positive
681271.0,UPDATE: Cowen & Company Upgraded Ironwood Pharmaceuticals,2013-10-24 15:14:00-04:00,IRWD,neutral
681272.0,"Cowen & Company Upgrades Ironwood Pharmaceuticals, Inc. to Outperform, Maintains $14.00 PT",2013-10-24 09:32:00-04:00,IRWD,neutral
681273.0,Stocks Hitting 52-Week Lows,2013-10-22 10:13:00-04:00,IRWD,negative
681274.0,"Ironwood Pharmaceuticals, Inc. Reports Q3 EPS of $(0.51) vs $(0.57) Est; Revenue of $4.93M vs $6.54M Est; Reaffirms Outlook",2013-10-22 07:13:00-04:00,IRWD,neutral
681275.0,"Ironwood Pharma Shares Lower Following Market Perform Rating, $15 Target at BMO",2013-09-23 10:24:00-04:00,IRWD,neutral
681276.0,"Goldman Sachs Initiates Coverage on Ironwood Pharmaceuticals, Inc. at Sell, Announces $9.50 PT",2013-09-17 07:09:00-04:00,IRWD,neutral
681277.0,UPDATE: Cantor Fitzgerald Upgrades Ironwood Pharmaceuticals Following Model Update,2013-07-24 10:40:00-04:00,IRWD,neutral
681278.0,"Jefferies Maintains Hold on Ironwood Pharmaceuticals, Inc., Lowers PT to $12.00",2013-07-24 09:28:00-04:00,IRWD,negative
681279.0,"Janney Capital Upgrades Ironwood Pharmaceuticals, Inc. to Buy",2013-07-24 07:38:00-04:00,IRWD,neutral
681280.0,Benzinga's Top Upgrades,2013-07-24 07:36:00-04:00,IRWD,positive
681281.0,"Cantor Fitzgerald Upgrades Ironwood Pharmaceuticals, Inc. to Hold, Raises PT to $10.00",2013-07-24 07:18:00-04:00,IRWD,neutral
681282.0,Benzinga's Top Pre-Market Gainers,2013-07-23 08:28:00-04:00,IRWD,positive
681283.0,"Ironwood Pharmaceuticals, Inc. Reports Q2 EPS of $(0.57) vs $(0.68) Est; Revenue of $9.66M vs $6.48M Est",2013-07-23 07:10:00-04:00,IRWD,neutral
681284.0,Stocks Hitting 52-Week Lows,2013-06-28 10:26:00-04:00,IRWD,negative
681285.0,UPDATE: Cantor Fitzgerald Lowers PT on Ironwood Pharmaceuticals on Lower than Expected Constella Pricing,2013-06-25 13:57:00-04:00,IRWD,negative
681286.0,Benzinga's Top Initiations,2013-06-21 07:43:00-04:00,IRWD,positive
681287.0,"Credit Suisse Initiates Coverage on Ironwood Pharmaceuticals, Inc. at Outperform, Announces $16.00 PT",2013-06-21 06:30:00-04:00,IRWD,positive
681288.0,Ironwood Pharma Reports Potential Reduction in Commercial Launch Milestones from $20M to $17M,2013-06-12 08:04:00-04:00,IRWD,neutral
681289.0,Ironwood Pharmaceuticals Announces Partial Exercise of Underwriters' Option in Public Offering of Common Stock ,2013-06-04 16:00:00-04:00,IRWD,neutral
681290.0,UPDATE: Webush Upgrades Ironwood Pharmaceuticals on Completed Financing,2013-05-30 10:42:00-04:00,IRWD,neutral
681291.0,Benzinga's Top Upgrades,2013-05-30 07:46:00-04:00,IRWD,positive
681292.0,"Wedbush Upgrades Ironwood Pharmaceuticals, Inc. to Neutral, Maintains $12.00 PT",2013-05-30 07:28:00-04:00,IRWD,neutral
681293.0,Benzinga's Top Pre-Market Losers,2013-05-21 08:21:00-04:00,IRWD,negative
681294.0,Ironwood Pharmaceuticals Announces 10.5M Share Proposed Public Offering of Common Stock ,2013-05-20 16:07:00-04:00,IRWD,positive
681295.0,"Mid-Morning Market Update: Markets Open Mixed, Tyson Posts Downbeat Profit",2013-05-06 11:04:00-04:00,IRWD,positive
681296.0,"Cowen & Company Downgrades Ironwood Pharmaceuticals, Inc. to Neutral",2013-05-06 09:38:00-04:00,IRWD,neutral
681297.0,UPDATE: Wedbush Downgrades Ironwood Pharmaceuticals to Underperform on Higher Lizness Costs,2013-04-24 10:39:00-04:00,IRWD,neutral
681298.0,UPDATE: Morgan Stanley Downgrades Ironwood Pharmaceuticals to Equal-Weight on Lower Linzess Sales Estimates,2013-04-24 10:38:00-04:00,IRWD,negative
681299.0,"Wedbush Downgrades Ironwood Pharmaceuticals, Inc. to Underperform, Lowers PT to $12.00",2013-04-24 07:53:00-04:00,IRWD,negative
681300.0,"Morgan Stanley Downgrades Ironwood Pharmaceuticals, Inc. to Equal-weight, Lowers PT to $18.00",2013-04-24 06:43:00-04:00,IRWD,negative
681301.0,"Market Wrap for Tuesday, April 23: Major Averges Climb Better Than 1% Despite Mini Flash-Crash",2013-04-23 16:31:00-04:00,IRWD,positive
681302.0,"Aegis Capital Maintains Buy on Ironwood Pharmaceuticals, Inc., Lowers PT to $17.00",2013-04-23 13:24:00-04:00,IRWD,negative
681303.0,"Mid-Morning Market Update: Markets Surge On Earnings, Lockheed Martin Posts Upbeat Profit",2013-04-23 10:47:00-04:00,IRWD,positive
681304.0,"Ironwood Pharmaceuticals, Inc. Reports Q1 EPS of $(0.87) vs $(0.64) Est; Revenue of $3.30M vs $8.94M Est",2013-04-23 07:11:00-04:00,IRWD,neutral
681305.0,UPDATE: Credit Suisse Upgrades Ironwood Pharmaceuticals to Outperform on Positive Linzess Survey,2013-03-15 08:54:00-04:00,IRWD,positive
681306.0,"Credit Suisse Upgrades Ironwood Pharmaceuticals, Inc. to Outperform, Raises PT to $24.00",2013-03-15 07:12:00-04:00,IRWD,positive
681307.0,Bank of America Raises PT on Ironwood Pharmaceuticals on Positive Prescription Data,2013-03-12 08:12:00-04:00,IRWD,positive
681308.0,"Bank of America Maintains Neutral on Ironwood Pharmaceuticals, Inc., Raises PO to $18.00",2013-03-12 07:51:00-04:00,IRWD,negative
681309.0,UPDATE: Wedbush Upgrades Ironwood Pharmaceuticals to Neutral on LINZESS Strength,2013-02-13 08:04:00-05:00,IRWD,positive
681310.0,"Wedbush Upgrades Ironwood Pharmaceuticals, Inc. to Neutral, Raises PT to $13.00",2013-02-13 07:13:00-05:00,IRWD,neutral
681311.0,"Ironwood Pharma Promotes Dr. Mark Currie to Senior VP, Chief Scientific Officer, Pres of R&D",2013-02-11 09:27:00-05:00,IRWD,positive
681312.0,"Janney Capital Initiates Coverage on Ironwood Pharmaceuticals, Inc. at Neutral, Announces $14.00 PT",2013-01-31 09:12:00-05:00,IRWD,neutral
681313.0,Ironwood Pharma Shares Tumble Follow UBS Downgrade to Sell,2013-01-16 11:51:00-05:00,IRWD,positive
681314.0,"JP Morgan Maintains Overweight on Ironwood Pharmaceuticals, Inc., Raises PT to $25.00",2013-01-15 14:45:00-05:00,IRWD,neutral
681315.0,"Aegis Capital Maintains Buy on Ironwood Pharmaceuticals, Inc., Raises PT to $19.00",2013-01-15 11:13:00-05:00,IRWD,neutral
681316.0,"Ironwood Pharmaceuticals, Inc. Reports Q4 EPS of $(0.41) vs $(0.49) Est; Revenue of $27.0M vs $16.85M Est",2013-01-15 07:50:00-05:00,IRWD,neutral
681317.0,"Earnings Scheduled For January 15, 2013 ",2013-01-15 02:06:00-05:00,IRWD,neutral
681318.0,Ironwood Starts Phase I Trial of Anti-Anxiety Drug in US ,2012-12-21 06:36:00-05:00,IRWD,neutral
681319.0,"Ironwood Pharma, Forest Labs' Announces US Availability of Linzess to Treat IBS with Constipation",2012-12-17 08:17:00-05:00,IRWD,positive
681320.0,EC Approves Ironwood's Constella for Treatment of Irritable Bowel Syndrome with Constipation in Adults ,2012-11-28 06:09:00-05:00,IRWD,negative
681321.0,"Mizuho Initiates Coverage on Ironwood Pharmaceuticals at Buy, Announces PT of $22",2012-11-08 17:33:00-05:00,IRWD,neutral
681322.0,"Aegis Capital  Maintains Ironwood Pharmaceuticals at Buy, Raises PT from $17 to $18",2012-10-24 15:20:00-04:00,IRWD,neutral
681323.0,Ironwood and AstraZeneca Announce Linaclotide Collaboration for China  ,2012-10-23 09:13:00-04:00,IRWD,neutral
681324.0,From Earlier: Ironwood Pharmaceuticals Reports Q3 EPS $0.42 May Not Compare to $0.13 Est; Revenues $96.4M vs $75.90M Est,2012-10-16 09:58:00-04:00,IRWD,neutral
681325.0,"UPDATE: Ironwood Pharmaceuticals Rises, then Falls Following FDA Approval",2012-08-30 14:22:00-04:00,IRWD,positive
681326.0,Ironwood Pharmaceuticals Resumes Trading,2012-08-30 14:20:00-04:00,IRWD,neutral
681327.0,PREVIEW: Ironwood Pharmaceuticals to Resume Trading at 2:20pm,2012-08-30 14:03:00-04:00,IRWD,neutral
681328.0,Ironwood and Forest Announce FDA Approval of LINZESSTM ,2012-08-30 14:01:00-04:00,IRWD,positive
681329.0,UPDATE: Ironwood Pharmaceuticals Still Halted; No Resumption Time,2012-08-30 12:39:00-04:00,IRWD,negative
681330.0,"Ironwood, Forest Labs Get FDA Approval for Linzess",2012-08-30 11:00:00-04:00,IRWD,positive
681331.0,Ironwood Pharma Trade Halt,2012-08-30 10:13:00-04:00,IRWD,neutral
681332.0,UPDATE: Cantor Fitzgerald Raises PT to $8 on Ironwood Pharmaceuticals; Maintains Sell  ,2012-08-20 10:51:00-04:00,IRWD,neutral
681333.0,"Cantor Fitzgerald Maintains Ironwood Pharmaceuticals at Sell, Raises PT from $7 to $8",2012-08-20 06:42:00-04:00,IRWD,neutral
681334.0,Biotechs With Upcoming PDUFA Dates,2012-07-18 15:09:00-04:00,IRWD,neutral
681335.0,"UPDATE: Cantor Fitzgerald Reiterates Sell Rating, Lowers PT on Ironwood Pharmaceuticals",2012-07-18 10:47:00-04:00,IRWD,negative
681336.0,"Cantor Fitzgerald Maintains Ironwood Pharmaceuticals at Sell, Lowers PT from $10 to $7",2012-07-18 06:43:00-04:00,IRWD,negative
681337.0,"UPDATE: Aegis Capital Initiated Ironwood Pharmaceuticals with Buy, $17 PT; Unique Gastrointestinal Opportunity  ",2012-07-09 09:42:00-04:00,IRWD,positive
681338.0,"Aegis Capital Initiates Coverage on Ironwood Pharmaceuticals at Buy, Announces PT of $17",2012-07-09 05:54:00-04:00,IRWD,neutral
681339.0,"Bank of America Maintains Ironwood Pharmaceuticals at Neutral, Lowers PO from $16 to $15",2012-05-08 12:13:00-04:00,IRWD,negative
681340.0,"Ladenburg Thalmann Maintains Ironwood Pharmaceuticals at Buy, Lowers PT from $17 to $16",2012-05-01 11:46:00-04:00,IRWD,negative
681341.0,Ironwood Pharmaceuticals Provides First Quarter 2012 Investor Update   ,2012-05-01 06:32:00-04:00,IRWD,neutral
681342.0,From Earlier: Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012  ,2012-04-23 07:53:00-04:00,IRWD,neutral
681343.0,"UBS Initiates Coverage on Ironwood Pharmaceuticals at Neutral, Announces PT of $14",2012-04-12 12:23:00-04:00,IRWD,neutral
681344.0,UPDATE: Wedbush Downgrades Ironwood Pharmaceuticals; Lowers PT,2012-03-05 09:39:00-05:00,IRWD,negative
681345.0,Bank of America: Zelnorm vs. linaclotide ,2012-03-05 08:46:00-05:00,IRWD,neutral
681346.0,"Wedbush Securities Downgrades Ironwood Pharmaceuticals from Outperform to Underperform, Lowers PT from $20 to $8",2012-03-05 07:43:00-05:00,IRWD,positive
681347.0,"UPDATE: Cantor Fitzgerald Downgrades Ironwood Pharmaceuticals, Lowers PT",2012-02-29 09:04:00-05:00,IRWD,negative
681348.0,"Cantor Fitzgerald Downgrades Ironwood Pharmaceuticals from Hold to Sell, Maintains PT at $10",2012-02-29 06:36:00-05:00,IRWD,neutral
681349.0,Ironwood Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock,2012-02-13 09:14:00-05:00,IRWD,neutral
681350.0,From Earlier: Ironwood Pharmaceuticals Prices Public Offering of 5.25M Shares at $15.09 ,2012-02-10 07:18:00-05:00,IRWD,positive
681351.0,From Earlier: Ironwood Announces FDA Advisory Committee Meeting Will Not Be Scheduled in Connection with New Drug Application for Linaclotide  ,2012-02-09 06:56:00-05:00,IRWD,neutral
681352.0,Ironwood Pharmaceuticals Announces Proposed Public Offering of 5.25M Shares,2012-02-08 16:57:00-05:00,IRWD,positive
681353.0,Ironwood Pharmaceuticals Spiking Lower,2012-02-08 12:02:00-05:00,IRWD,negative
681354.0,"Ironwood Pharmaceuticals and Bionomics Announce Collaboration, Research, and License Agreement   ",2012-01-04 17:01:00-05:00,IRWD,positive
681355.0,European Patent Office Upholds Synergy Pharmaceuticals' Grant of Claims to Plecanatide   ,2012-01-04 06:52:00-05:00,IRWD,positive
681356.0,Synergy Pharmaceuticals Files Suit Against Ironwood Pharmaceuticals,2011-12-13 08:06:00-05:00,IRWD,neutral
681357.0,"Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals and its Chief Scientific Officer",2011-12-13 06:57:00-05:00,IRWD,neutral
681358.0,Ironwood Pharmaceuticals Reports Q3 Revenues $12.20M vs $12.92M Est	,2011-11-07 16:16:00-05:00,IRWD,neutral
681359.0,Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review  ,2011-10-24 06:23:00-04:00,IRWD,negative
681360.0,Ironwood Announces Linaclotide European Regulatory Submission for the Treatment of Irritable Bowel Syndrome with Constipation   ,2011-09-29 06:45:00-04:00,IRWD,negative
681361.0,Notable Call Options Activity in Ironwood Pharmaceuticals,2011-09-01 11:27:00-04:00,IRWD,neutral
681362.0,Ladenburg Thalmann Lowers PT on Ironwood Pharmaceuticals To $16,2011-08-12 08:54:00-04:00,IRWD,negative
681363.0,Earnings Scheduled For August 11,2011-08-11 03:43:00-04:00,IRWD,neutral
681364.0,Ironwood Pharmaceuticals and Forest Laboratories Announce Submission of New Drug Application for Linaclotide ,2011-08-09 16:27:00-04:00,IRWD,neutral
681365.0,Will FDA Push Through New Constipation Drug?,2011-08-09 16:14:00-04:00,IRWD,neutral
681366.0,"Ironwood Pharmaceuticals Halted, Pending News",2011-08-09 16:02:00-04:00,IRWD,neutral
681367.0,"Earnings Scheduled For May 12 (DRYS, JWN, AHII, KSS, DAR, NVDA, CACH, XIN, ACAT, BBOX, ESLR, CXPO, IRWD, CTFO, TREE, CYCC, CXDC)",2011-05-12 02:15:00-04:00,IRWD,neutral
681368.0,UPDATE: Bank of America Merrill Lynch Raises PO on Ironwood Pharmaceuticals to $16 (IRWD),2011-05-11 08:58:00-04:00,IRWD,negative
681369.0,"Ironwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation (IRWD, FRX)",2011-05-04 08:04:00-04:00,IRWD,negative
681370.0,J.P. Morgan Raises PT On IRWD To $21,2011-04-15 08:06:00-04:00,IRWD,neutral
681371.0,Ironwood Pharmaceuticals Hits 52-Week High (IRWD),2011-04-14 11:04:00-04:00,IRWD,neutral
681372.0,Ironwood Pharmaceuticals Hits 52-Week High (IRWD),2011-04-14 10:52:00-04:00,IRWD,neutral
681373.0,Morgan Stanley Initiates OW Rating For IRWD,2011-03-18 07:59:00-04:00,IRWD,neutral
681374.0,Ironwood Pharmaceuticals Reports Q4 Loss of $0.12 per share,2011-03-03 06:26:00-05:00,IRWD,neutral
681375.0,"Earnings Scheduled For March 3 (MRVL, HNZ, KR, NOVL, ALTH, BIG, BRLI, ACU, CLDX, ADUS, ACCL, IRWD)",2011-03-03 03:42:00-05:00,IRWD,neutral
681376.0,Ironwood and Protagonist Establish Collaboration ,2011-01-18 16:14:00-05:00,IRWD,neutral
681377.0,Forest Labs Impresses Again - Analyst Blog,2011-01-18 13:01:00-05:00,IRWD,positive
681378.0,Forest Labs Impresses Again - Analyst Blog,2011-01-18 12:45:00-05:00,IRWD,positive
681379.0,J.P. Morgan Reiterates Overweight Rating On Shares Of Ironwood Pharmaceuticals,2010-11-02 08:31:00-04:00,IRWD,negative
681380.0,"Benzinga's Top Pre-Market NASDAQ Gainers (IRWD, AINV, CRUS, AONE)",2010-09-14 08:56:00-04:00,IRWD,positive
681381.0,Ironwood (IRWD) To Raise $267 Million Through IPO,2010-02-01 08:40:00-05:00,IRWD,neutral
